🇺🇸 TIPRANAVIR in United States

FDA authorised TIPRANAVIR on 11 August 2006 · 1,050 US adverse-event reports

Marketing authorisation

FDA — authorised 11 August 2006

  • Application: NDA021814
  • Marketing authorisation holder: BOEHRINGER INGELHEIM
  • Indication: Labeling
  • Status: approved

Read official source →

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Death — 136 reports (12.95%)
  2. Nausea — 128 reports (12.19%)
  3. Vomiting — 121 reports (11.52%)
  4. Pneumonia — 112 reports (10.67%)
  5. Hepatotoxicity — 95 reports (9.05%)
  6. Cholelithiasis — 93 reports (8.86%)
  7. Condition Aggravated — 93 reports (8.86%)
  8. Hepatic Enzyme Increased — 91 reports (8.67%)
  9. Oedema Peripheral — 91 reports (8.67%)
  10. Schizophrenia — 90 reports (8.57%)

Source database →

TIPRANAVIR in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is TIPRANAVIR approved in United States?

Yes. FDA authorised it on 11 August 2006.

Who is the marketing authorisation holder for TIPRANAVIR in United States?

BOEHRINGER INGELHEIM holds the US marketing authorisation.